Ticker > Company >

Haleos Labs share price

Haleos Labs Ltd.

NSE: SMSLIFE BSE: 540679 SECTOR: Pharmaceuticals & Drugs  26.43 K   31   2

1145.00
+43.40 (3.94%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 1219

Today's Low

₹ 1135

52 Week High

₹ 1680

52 Week Low

₹ 956.05

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

346.17 Cr.

Enterprise Value

423.93 Cr.

No. of Shares

0.3 Cr.

P/E

17.25

P/B

1.71

Face Value

₹ 10

Div. Yield

0.13 %

Book Value (TTM)

₹  669.25

CASH

1.41 Cr.

DEBT

79.17 Cr.

Promoter Holding

71.41 %

EPS (TTM)

₹  66.38

Sales Growth

11.12%

ROE

11.45 %

ROCE

14.03%

Profit Growth

63.57 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year11.12%
3 Year-1.2%
5 Year5.35%

Profit Growth

1 Year63.57%
3 Year-5.57%
5 Year18.5%

ROE%

1 Year11.45%
3 Year9.17%
5 Year11.36%

ROCE %

1 Year14.03%
3 Year11.73%
5 Year13.86%

Debt/Equity

0.4015

Price to Cash Flow

12.35

Interest Cover Ratio

4.7845

CFO/PAT (5 Yr. Avg.)

0.630163079414501

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2025 71.41 0.00
Jun 2025 71.41 0.00
Mar 2025 71.41 0.00
Dec 2024 71.41 0.00
Sep 2024 71.41 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company’s PEG ratio is 0.271344619657492.
  • The company has an efficient Cash Conversion Cycle of 20.3093 days.
  • The company has a high promoter holding of 71.41%.

 Limitations

  • The company has shown a poor profit growth of -5.57167070315153% for the Past 3 years.
  • The company has shown a poor revenue growth of -1.19635265784861% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 86.57 78.5 82.88 85.43 79.04
Total Expenditure 72.8 66.7 69.81 79.83 68.21
Operating Profit 13.77 11.8 13.07 5.6 10.84
Other Income 0.43 1.26 0.06 2.2 1.01
Interest 2.16 1.93 1.96 1.84 1.73
Depreciation 2.5 2.57 2.56 2.62 2.63
Exceptional Items 0 0 0 0 0
Profit Before Tax 9.54 8.56 8.61 3.33 7.48
Tax 3.08 2.55 2.38 0.66 2.32
Profit After Tax 6.46 6.01 6.23 2.67 5.16
Adjusted EPS (Rs) 21.37 19.87 20.6 8.85 17.07

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 260.26 345.63 315.24 300 333.37
Total Expenditure 230.45 314.21 288.77 265.46 289.08
Operating Profit 29.8 31.42 26.48 34.54 44.29
Other Income 1.33 1.54 2.88 3.84 3.95
Interest 4.57 4.68 5.16 9.01 7.94
Depreciation 7.21 7.99 8.17 10.25 10.26
Exceptional Items 0 12.69 2.35 0 0
Profit Before Tax 19.35 32.98 18.37 19.11 30.04
Tax 6.19 7.6 5.15 6.05 8.67
Net Profit 13.17 25.38 13.22 13.07 21.37
Adjusted EPS (Rs.) 43.56 83.95 43.72 43.22 70.69

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 3.02 3.02 3.02 3.02 3.02
Total Reserves 123.31 148.19 161 173.2 194.15
Borrowings 21.63 26.85 45.97 28.31 17.31
Other N/C liabilities 18.79 14.98 16.83 20.13 19.53
Current liabilities 109.39 126.17 114.07 126.89 133.3
Total Liabilities 276.15 319.21 340.89 351.57 367.31
Assets
Net Block 100.83 98.72 139.61 138.23 150.23
Capital WIP 3.16 21.21 0.85 6 0.4
Intangible WIP 0 0 0 0 0
Investments 25.81 23.24 23.23 23.23 23.23
Loans & Advances 6.52 6.52 6.1 5.42 6.66
Other N/C Assets 0 0 0 0 0
Current Assets 139.83 169.52 171.09 178.68 186.79
Total Assets 276.15 319.21 340.89 351.57 367.31
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 19.35 20.28 16.02 19.11 30.04
Adjustment 9.89 10.52 11.51 15.4 18.85
Changes in Assets & Liabilities -3.02 -37.9 -19.45 -16.76 -12.36
Tax Paid -4.61 -7.56 -3.5 -3 -8.5
Operating Cash Flow 21.62 -14.66 4.58 14.75 28.03
Investing Cash Flow -5.94 -7.49 -27.96 -13.75 -13.77
Financing Cash Flow -7.87 14.63 22.59 -0.82 -14.2
Net Cash Flow 7.81 -7.52 -0.8 0.18 0.07

Corporate Actions

Investors Details

PARTICULARS Sep 2024% Dec 2024% Mar 2025% Jun 2025% Sep 2025%
promoters 71.41 71.41 71.41 71.41 71.41
annapurna talluri 24.56 24.56 24.56 24.56 24.56
hima bindu potluri 2.76 2.76 2.76 2.76 2.76
potluri infra projects ll... 0.26 0.26 0.26 0.26 0.26
ramesh babu potluri 7.94 7.94 7.94 7.94 7.94
sudeepthi gopineedi 2.61 2.61 6.60 6.60 6.60
sukumari koneru 0.02 0.02 0.02 0.02 0.02
trilok potluri 2.58 2.58 2.58 2.58 2.58
tvvsn murthy 15.88 15.88 15.88 15.88 15.88
vamsi krishna potluri 2.42 2.42 2.42 2.42 2.42
venkata chaitanya gopinee... 0.01 0.01 0.01 0.01 0.01
venkata praveen talluri 4.37 4.37 8.36 8.36 8.36
tvvsn murthy (huf) (karta... 7.98 7.98 - - -
PARTICULARS Sep 2024% Dec 2024% Mar 2025% Jun 2025% Sep 2025%
investors 28.59 28.59 28.59 28.59 28.59
bharadhwajan jaganathan v... 1.03 1.03 1.03 1.03 1.03
harita projects private 1.57 1.57 1.57 1.57 1.76

Annual Reports

Title Link
Title Link
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CARE
Credit CARE
Credit CARE RATINGS
Credit CARE RATINGS
Credit CARE RATINGS
Credit CARE RATINGS
Credit CARE
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

Haleos Labs informs about certificate 14 Oct, 10:24 AM SMS Lifesciences India informs about closure of trading window 20 Sep, 5:09 PM SMS Lifesciences - Quaterly Results 11 Aug, 3:11 PM SMS Lifesciences - Quaterly Results 11 Aug, 3:11 PM SMS Lifesciences - Quaterly Results 11 Aug, 3:11 PM SMS Lifesciences India receives EIR with VAI for Telangana facility 16 Jul, 2:42 PM SMS Lifesciences India informs about receipt of EIR 16 Jul, 12:32 PM USFDA completes inspection at SMS Lifesciences’ API manufacturing facility in Telangana 9 May, 4:42 PM SMS Lifesciences India informs about annual disclosure 5 Apr, 3:22 PM SMS Lifesciences India informs about disclosure 5 Apr, 2:32 PM SMS Lifesciences India informs about disclosure 20 Mar, 9:59 AM SMS Lifesciences India informs about disclosure 20 Mar, 9:58 AM SMS Lifesciences - Quaterly Results 12 Feb, 6:39 PM SMS Lifesciences - Quaterly Results 12 Feb, 6:39 PM SMS Lifesciences India informs about newspaper publication 28 Jan, 2:52 PM SMS Lifesciences India informs about event calendar related to 18th AGM 24 Aug, 11:37 AM SMS Lifesciences India informs about book closure 24 Aug, 11:35 AM SMS Lifesciences - Quaterly Results 9 Aug, 2:43 PM SMS Lifesciences - Quaterly Results 9 Aug, 2:43 PM SMS Lifesciences - Quaterly Results 9 Aug, 2:43 PM SMS Lifesciences India informs about details of loss of certificate 29 Jul, 4:11 PM SMS Lifesciences India informs about communication to shareholders 25 Jul, 12:34 PM SMS Lifesciences - Quaterly Results 27 May, 5:45 PM SMS Lifesciences - Quaterly Results 27 May, 5:45 PM SMS Lifesciences - Quaterly Results 27 May, 5:45 PM SMS Lifesciences India informs about disclosure 25 Apr, 2:49 PM SMS Lifesciences India informs about certificate 11 Apr, 4:29 PM SMS Lifesciences India informs about disclosure 5 Apr, 3:48 PM SMS Lifesciences India informs about disclosure 26 Mar, 4:48 PM SMS Lifesciences India informs about revised disclosure 26 Mar, 2:45 PM SMS Lifesciences - Quaterly Results 10 Feb, 1:49 PM SMS Lifesciences - Quaterly Results 10 Feb, 1:49 PM SMS Lifesciences - Quaterly Results 10 Feb, 1:49 PM SMS Lifesciences India informs about board meeting 3 Feb, 4:31 PM SMS Lifesciences India informs about disclosure 31 Jan, 12:31 PM SMS Lifesciences India informs about certificate 11 Jan, 5:17 PM SMS Lifesciences India informs about disclosures 29 Dec, 12:57 PM SMS Lifesciences India informs about disclosures 15 Dec, 4:49 PM SMS Lifesciences India informs about newspaper publication 9 Aug, 12:58 PM SMS Lifesciences - Quaterly Results 8 Aug, 6:42 PM SMS Lifesciences - Quaterly Results 8 Aug, 6:42 PM SMS Lifesciences India submits board meeting intimation 22 May, 4:36 PM SMS Lifesciences India informs about closure of trading window 28 Mar, 5:02 PM SMS Lifesciences - Quaterly Results 10 Feb, 4:10 PM SMS Lifesciences - Quaterly Results 10 Feb, 4:10 PM SMS Lifesciences - Quaterly Results 10 Feb, 4:10 PM SMS Lifesciences India informs about closure of trading window 28 Dec, 10:00 AM SMS Lifesciences India informs about certificate 11 Oct, 12:37 PM SMS Lifesciences India informs about newspaper advertisements 11 Aug, 4:47 PM SMS Lifesciences - Quaterly Results 9 Aug, 2:09 PM

Haleos Labs Stock Price Analysis and Quick Research Report. Is Haleos Labs an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Haleos Labs. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Haleos Labs has a PE ratio of 17.3181041677337 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Haleos Labs has ROA of 5.9456% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Haleos Labs has a Current ratio of 1.4013.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Haleos Labs has a ROE of 11.4465%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Haleos Labs has a Debt to Equity ratio of 0.4015 which means that the company has low proportion of debt in its capital.

  • Sales growth: Haleos Labs has reported revenue growth of 11.1231% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Haleos Labs for the current financial year is 13.2851987725387%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Haleos Labs is Rs 1.5 and the yield is 0.1274%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Haleos Labs is Rs 66.3814. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Haleos Labs in Ticker for free. Also, one can get the intrinsic value of Haleos Labs by using Valuation Calculators, which are available with a Finology ONE subscription. 

Haleos Labs FAQs

Q1. What is Haleos Labs share price today?
Ans: The current share price of Haleos Labs is Rs 1149.6.

Q2. What is the market capitalisation of Haleos Labs?
Ans: Haleos Labs has a market capitalisation of Rs 347.55707352 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Haleos Labs?
Ans: The PE ratio of Haleos Labs is 17.3181041677337 and the P/B ratio of Haleos Labs is 1.71773527302742, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Haleos Labs share?
Ans: The 52-week high share price of Haleos Labs is Rs 1680, and the 52-week low share price of Haleos Labs is Rs 959.8.

Q5. Does Haleos Labs pay dividends?
Ans: Currently, Haleos Labs pays dividends. Dividend yield of Haleos Labs is around 0.1274%.

Q6. What are the face value and book value of Haleos Labs shares?
Ans: The face value of Haleos Labs shares is Rs 10, while the book value per share of Haleos Labs is around Rs 669.2533. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Haleos Labs?
Ans: Haleos Labs has a total debt of Rs 79.1725 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Haleos Labs?
Ans: The ROE of Haleos Labs is 11.4465% and ROCE of Haleos Labs is 14.0324%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Haleos Labs a good buy for the long term?
Ans: The Haleos Labs long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Haleos Labs undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Haleos Labs appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Haleos Labs’s financials?
Ans: You can review Haleos Labs’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Haleos Labs
X